Navigation Links
Karolinska Development Invests in EvoStem Finland Oy

STOCKHOLM, January 12 /PRNewswire/ -- Sweden The Swedish investment company Karolinska Development AB has made a significant investment in EvoStem Finland Oy that develops stem cell and other tissue engineering based treatments for veterinary and human use.

In 2007 EvoStem Finland Oy introduced its first product TendoStem(R), which is a stem cell based treatment service for tendon and ligament injuries in horses. TendoStem(R) is currently on the market in Scandinavia.

"With this investment, we will speed up our international growth and product development projects," says Dr. Minna Leppanen, the CEO of EvoStem Finland Oy.

"We are targeting global markets, and currently we are engaged in negotiations for expansion of our market area. The investment of Karolinska Development AB and its strong, long-time commitment gives us a solid ground for a long-term development of our company," Leppanen continues.

"EvoStem has demonstrated that stem cell therapy for regenerative medicine is ready for the market. With our investment in EvoStem we strengthen our presence in the cell therapy area where we expect strong growth and medical progress," comments Investment Manager Hans-Peter Ekre, Karolinska Development AB.

About EvoStem Finland Oy

EvoStem Finland Oy develops, produces and markets stem cell based treatment methods for animals and man. The company's current focus is on orthopaedic and sports medicine applications. EvoStem Finland Oy was founded in 2005 as a spin-off of Tampere University Institute of Regenerative Medicine Regea and is based in Tampere, Finland.

About Karolinska Development

Managing one of the largest portfolios of life science research companies in Europe, Karolinska Development is a Swedish investment company using a unique, highly cost effective model to commercialize internationally renowned life science innovations. Professionals in business development and management, supported by a network of experienced technical specialists, ensure fast and efficient development. This enables Karolinska Development to rapidly build value in high risk opportunities, through long term lead investor position from seed stage; developing the medical products of the future. Karolinska Development's office is located at the Karolinska Institutet Science Park, Solna/Stockholm Sweden.

    For more information, please contact:
    CEO Minna Leppanen, EvoStem Finland Oy,
    mobile +358-40-504-4423,

    Investment Manager Hans-Peter Ekre, Karolinska Development AB,
    mobile +46-70-533-67-47,

SOURCE Karolinska Development and EvoStem
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Dr. Henry Barnett becomes first person outside Europe to receive Karolinska Stroke Award
2. The Feinstein to collaborate with Swedens Karolinska Institute
3. 3 new honorary doctors at Karolinska Institutet
4. Karolinska Institutets Pedersen to receive GSAs 2007 Distinguished Career Award
5. Reduce Risk, Achieve Compliance and Accelerate Time to Market with hiQual and Hiemstra Product Development
6. Blog Launched to Discuss Developments in Hydrophilic Coatings for Medical Devices
7. New Markets Development Program Brings Renovations, Equipment to Bastrop, Louisiana Hospital
8. New drug development still takes 8 years despite faster FDA review, according to Tufts CSDD
9. The Leukemia & Lymphoma Society and The University of Kansas Cancer Center Announce Innovative Partnership to Accelerate Drug Development
10. BioMarin and La Jolla Pharmaceutical Sign Worldwide (Excluding Asia Pacific) Development and Commercialization Agreement for Riquent
11. New Zealand Waynes New Resources Development Co., Ltd. Completes Reverse Merger to Go Public in the U.S.
Post Your Comments:
(Date:11/27/2015)... ... November 27, 2015 , ... According to an article published ... Toronto and the University of British Columbia suggested that laws requiring bicyclists to wear ... explains that part of the reason for the controversial conclusion is that, while helmets ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... A team ... ways to treat it. Surviving Mesothelioma has just posted the findings on the ... University Hospital Zurich analyzed the cases of 136 mesothelioma patients who were treated with ...
(Date:11/27/2015)... ... November 27, 2015 , ... Lizzie’s Lice Pickers just announced a special promotion ... off of their purchase of lice treatment product. In addition, customers will receive a ... company spokesperson. “Finding lice is a sure way to ruin the holidays, so we ...
(Date:11/27/2015)... ANGELES, CA (PRWEB) , ... November 27, 2015 , ... MPWH, the No.1 Herpes-only dating ... of 30 (see Table 1-1 ). More than 3.7 billion people under the ... virus type 1 (HSV-1), according to WHO's first global estimates of HSV-1 infection . ...
(Date:11/27/2015)... ... November 27, 2015 , ... A simply groundbreaking television series, "Voices in America", ... delves into an array of issues that are presently affecting Americans. Dedicated to providing ... this show is changing the subjects consumers focus on, one episode at a time. ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... WILMINGTON, N.C. , Nov. 25, 2015 /PRNewswire/ ... announces the planned investment of at least $15.8 ... in Wilmington, NC . The ... services capacity to meet the growing demands of ... Wilmington site expansion will provide up ...
(Date:11/25/2015)... N.Y. , Nov. 25, 2015  Henry Schein, ... and services to office-based dental, medical and animal health ... (GNYDM) Meeting the Henry Schein ConnectDental® Pavilion , ... broadest array of open solutions designed to help any ... Click here for a schedule of experts ...
(Date:11/25/2015)... , Nov. 25, 2015  Trovagene, Inc. (NASDAQ: ... announced that Chief Executive Officer Antonius Schuh, Ph.D., is ... th Annual Piper Jaffray Healthcare Conference. ... New York Palace Hotel in New York ... p.m. EST. Mr. Schuh will be available for one-on-one ...
Breaking Medicine Technology: